parathyroid hormone  (ALPCO)

Journal: Journal of the Endocrine Society

Article Title: Subclinically low BMD in young men is associated with compromised bone microarchitecture and lower lean mass

doi: 10.1210/jendso/bvag003

Figure Lengend Snippet: Biomarkers. Fig. 1 depicts all assessed biomarker concentrations. The total hip, femoral neck, or lumbar spine (Lower) group is depicted in black filled circles, while the control (Con) group is in clear squares. A, P1NP (pg/mL); B, alkaline phosphatase (ALP) (pg/mL); C, tartrate-resistant acid phosphatase 5b (TRAP5b) (U/L); D, sclerostin (pmol/L); E, β C-terminal cross-linked telopeptide of type I collagen (βCTX) (pmol/L); F, testosterone (ng/mL); G, estradiol (pg/mL); H, parathyroid hormone (PTH) (pg/mL); I, insulin-like growth factor-1 (IGF-1) (ng/mL); J, insulin-like growth factor-1 binding protein 5 (IGFBP-5) (ng/mL).

Article Snippet: Commercially available enzyme-linked immunosorbent assays were used to determine circulating concentrations of serum procollagen type I N-terminal propeptide (PINP; Novus catalog No. NBP2-76465, RRID:AB_3720306, 1:200 dilution, CV 5.3%, sensitivity 9.4 pg/mL), alkaline phosphatase (ALP; Novus catalog No. NBP2-68197, RRID:AB_3720307, CV 6.0%, sensitivity 46.9 pg/mL), tartrate-resistant acid phosphatase 5b (TRAP5b; Immunodiagnostic Systems catalog No. SB-TR201A, RRID:AB_3095995, CV 4.7%, sensitivity 0.4 U/L), sclerostin (Biomedica catalog No. BI-20492, RRID:AB_2894889, CV 6.4%, sensitivity 3.2 pmol/L), testosterone (Alpco Diagnostics catalog No. 11-TESHU-E01, RRID:AB_3720308, CV 4.2%, sensitivity 0.02 ng/mL), estradiol (Alpco Diagnostics catalog No. 11-ESTHU-E01, RRID:AB_2756385, CV 7.6%, sensitivity 10 pg/mL), insulin like growth factor-1 (IGF-1; Alpco Diagnostics catalog No. 22-IGFHU-E01, RRID:AB_2923276, 1:20 dilution, average CV 3.3%, assay sensitivity 9.4 pg/mL), IGF binding protein-5 (IGFBP-5; R and D Systems catalog No. DY875, RRID:AB_3720311, 3× dilution, CV 2.7%), parathyroid hormone (PTH; (Alpco Diagnostics catalog No. 21-IPTHU-E01, RRID:AB_2943035), CV 7.3%, sensitivity 1.6 pg/mL), and plasma β C-terminal cross-linked telopeptide of type I collagen (βCTX; Immunodiagnostic Systems catalog No. IS-3000N, RRID:AB_3720313, CV 6.2%, sensitivity 3.2 pmol/L).

Techniques: Biomarker Discovery, Control, Binding Assay

Journal: bioRxiv

Article Title: TGFβ signaling regulates the response of the skeleton to phosphate

doi: 10.64898/2025.12.01.691659

Figure Lengend Snippet: 11 week old wildtype mice were treated with either control IgG or neutralizing pan-TGFB antibody (1D11) (at 5mg/kg) three times over one week and were placed on a normal phosphate (0.6% Pi) or high phosphate (1.8% Pi) diet. a. Serum TGFB2 and b. serum iFGF23 were assessed by ELISA. c. Femoral Fgf23 , Tgfb1 , and Tgfb2 gene expression was assessed by RT-qPCR, with fold change relative to mice on a normal phosphate diet treated with IgG, normalized using expression of Rplp0. d. Kidney Cyp27b1 , Cyp24a1 , and Klotho gene expression was assessed by RT-qPCR, with fold change relative to mice on a normal phosphate diet treated with IgG, normalized using expression of Rplp0. e. Urine phosphate measured was assessed with colorimetric quantification. (n=3 for mice on 1.8% Pi diet treated with IgG due to loss of samples). f. Serum phosphate was assessed with colorimetric quantification. g. Serum iPTH was assessed by ELISA. h. Serum creatinine was assessed by ELISA. n= 4-6 biological replicates for all experiments. Significance was assessed by two-way ANOVA, and corrected for multiple comparisons using Šidák’s correction (*: adjusted p-value<0.05, ns: not significant).

Article Snippet: Additional ELISAs were used to quantify serum TGFβ2 (DY7346-05, R&D Systems), serum intact parathyroid hormone (iPTH) (60-2305, QuidelOrtho), and urine creatinine concentrations (0430, Stanbio Laboratory).

Techniques: Control, Enzyme-linked Immunosorbent Assay, Gene Expression, Quantitative RT-PCR, Expressing